explore -WSS

explore

author：fashion 2025-10-04 07:30:20 - browse：5971

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Gene therapy for Afghan refugees’ infant will be fully covered

WSS

Medicare Advantage plans can’t deny care with AI, CMS warns

STAT Summit: The economic case for universal basic health care

Gene therapy for Afghan refugees’ infant will be fully covered

Problems with a popular proposal to regulate AI in health care

Why a market frenzy over new weight loss drugs defies logic

STAT Summit: How researchers deal with rejection

explore

explore

hotspot

Cancer drug shortages should be causing more outrage

Results on Novartis prostate cancer therapy could expand its use

How to save PrEP access — and even expand it

Top private equity targets in 2023: cardiology, clinical trials, lasers

Dobbs anniversary: the lost opportunity of abortion as health care

AstraZeneca stays mum on Medicare drug pricing negotiations

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Devoted Health’s losses in Medicare Advantage persist

DIEP, the 'gold standard' of breast reconstruction, is under threat

Top private equity targets in 2023: cardiology, clinical trials, lasers

focus

A protest over insulin prices is seen as a fight for life

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

The Biogen Aduhelm mess could happen again

Roivant's CEO is a star, but biotech's black hole persists

Health tech investors get more selective as pandemic boom fades

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

focus

knowledge

knowledge

focus